Quantification of risperidone and 9-hydroxyrisperidone in plasma and saliva from adult and pediatric patients by liquid chromatography-mass spectrometry.

[1]  P. F. M. Janssen,et al.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding , 1996, Psychopharmacology.

[2]  E. Günther,et al.  Flow‐Dependent Salivary Primidone Levels in Epileptic Children , 1979, Epilepsia.

[3]  A. Avenoso,et al.  Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone , 1999, Psychopharmacology.

[4]  J. Leysen,et al.  Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. , 1994, The Journal of clinical psychiatry.

[5]  O. Olesen,et al.  Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[6]  A. Labelle,et al.  Phase-IV Multicentre Clinical Study of Risperidone in the Treatment of Outpatients with Schizophrenia , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[7]  P Kellaway,et al.  Use of saliva in therapeutic drug monitoring. , 1977, Clinical chemistry.

[8]  J. Chaulet,et al.  Unreliability of saliva samples for monitoring chloroquine and proguanil levels during anti-malarial chemoprophylaxis. , 1996, General pharmacology.

[9]  J. Heykants,et al.  Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography. , 1992, Journal of chromatography.

[10]  J. de Gier,et al.  Complications in correlation studies between serum, free serum and saliva concentrations of nitrazepam. , 1987, Methods and findings in experimental and clinical pharmacology.

[11]  N. C. van de Merbel,et al.  Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  R. Logan,et al.  SALIVARY DRUG MEASUREMENT: A CAUTIONARY TALE , 1986, The Lancet.

[13]  W. Smyth,et al.  Electrospray ionisation-mass spectrometric characterisation of selected anti-psychotic drugs and their detection and determination in human hair samples by liquid chromatography-tandem mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[14]  J. Beijnen,et al.  Saliva as an Alternative Body Fluid for Therapeutic Drug Monitoring of the Nonnucleoside Reverse Transcription Inhibitor Nevirapine , 2001, Therapeutic drug monitoring.

[15]  L. Bertilsson,et al.  Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients , 2001, European Journal of Clinical Pharmacology.

[16]  G. Mannens,et al.  Absorption, metabolism, and excretion of risperidone in humans. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[17]  O. Olesen,et al.  Serum concentrations and side effects in psychiatric patients during risperidone therapy. , 1998, Therapeutic drug monitoring.

[18]  A. Peer,et al.  Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects , 1993, Clinical pharmacology and therapeutics.

[19]  S. Marder,et al.  Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. , 2000, Journal of mass spectrometry : JMS.